AGTX (Agentix) Common Stock: $0.04 Mil (As of Mar. 2026)


What is Agentix Common Stock?

Agentix AGTX Common Stock is $0.04 Mil as of Mar. 2026. The stock has 2 warning signs investors should review.

Agentix's quarterly common stock stayed the same from Sep. 2025 ($0.04 Mil) to Dec. 2025 ($0.04 Mil) and stayed the same from Dec. 2025 ($0.04 Mil) to Mar. 2026 ($0.04 Mil).

Agentix's annual common stock stayed the same from Mar. 2024 ($0.04 Mil) to Mar. 2025 ($0.04 Mil) and stayed the same from Mar. 2025 ($0.04 Mil) to Mar. 2026 ($0.04 Mil).

Agentix Common Stock Historical Data

* Premium members only.

The historical data trend for Agentix's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agentix Common Stock Chart

Agentix Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Mar23 Mar24 Mar25 Mar26
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.04 0.04 0.04 0.04

Agentix Quarterly Data
May21 Aug21 Nov21 Feb22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.04 0.04 0.04 0.04

Agentix Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.04 Mil mean?
Agentix (AGTX) has a Common Stock of $0.04 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Agentix and its competitors.
Is Agentix's Common Stock too high?
Agentix's current Common Stock is $0.04 Mil.
How does Agentix's Common Stock compare to BZYR and ATXI?
Agentix's Common Stock of $0.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Agentix and its competitors. Agentix's current Common Stock is $0.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agentix stock overvalued right now?
Agentix (AGTX) has a current Common Stock of $0.04 Mil. The current Common Stock is $0.04 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Agentix (AGTX), the current Common Stock is $0.04 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Agentix Business Description

Address 32932 Pacific Coast Highway, No. 14-254, Dana Point, CA, USA, 92629
Agentix Corp is a biotechnology company. Through its subsidiary, it is engaged in the development and commercialization of novel therapeutics to treat metabolic diseases, peripheral neuropathy, progressive lung disease, and ischemic reperfusion injury. Its principal business objective is to develop both science-driven synthetic and natural cannabinoid therapeutics that address unmet medical needs and continue to drive innovations in the endocannabinoid space. Its pipeline of drug candidates includes AGTX-2004, a CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus (T2DM), and AGTX-2003 a peripherally-acting CB1 receptor inverse agonist that has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver disease.